Safety and Efficacy of Trastuzumab BS
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
8actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-09 | actual | When the study began enrolling |
| Primary completion | 2025-03-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-27 | actual | The whole study's end, after follow-up |
| First posted | 2019-11-29 | actual | When this record first appeared on the registry |
| Results posted | 2026-04-14 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-04-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Gastric Cancer
Intervention
- Drug: TRASTUZUMAB BS
Primary outcome
what the primary-completion date above is the date OFThe Incidence of Adverse Drug Reactions (ADRs)
measured From Day 1 to 28 days after the last dose within 24 weeks; to the first dose after 24 weeks; or to the next treatment. If discontinued before 24 weeks, it was until 28 days after discontinuation or until the next treatment. Maximum duration was 28 weeks.
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-07-18 · 3.0 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-12-12 · 1.1 MB · SAP_001.pdf
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed